强化全身治疗联合立体定向消融放疗剂量对不可切除胰腺癌的长期影响
该单中心回顾性研究纳入2007年2月至2018年8月接受多分次立体定向消融放疗(SABR)的149例不可切除胰腺癌患者,中位随访15个月。结果显示,SABR剂量≥40 Gy联合mFFX方案(n=21)较吉西他滨为基础化疗联合SABR<40 Gy者,中位PFS(14 vs 10个月)和中位OS(24 vs 14个月)均更优。
要点
- 不可切除胰腺癌多分次SABR中位剂量33 Gy/5次,中位OS为16个月。
- SABR≥40 Gy联合mFFX较吉西他滨化疗联合SABR<40 Gy者PFS和OS更优。
- 联合组1年PFS和OS分别为67%和90%,对照组为35%和59%。
核心结论
- 采用mFFX联合5分次SABR剂量≥40 Gy可能优于吉西他滨为基础化疗或SABR剂量<40 Gy的方案。
研究设计与样本
- 单中心回顾性研究,纳入2007年2月至2018年8月接受多分次SABR的不可切除胰腺癌患者149例,中位随访15个月(范围5-47)。
主要发现
- 全组中位OS为16个月(95% CI 14-17),1年局部失败累积发生率为14%。
- SABR≥40 Gy联合mFFX组(n=21)较吉西他滨化疗联合SABR<40 Gy组中位PFS为14 vs 10个月(HR 0.46,95% CI 0.29-0.71,P=0.003)。
- 上述两组中位OS为24 vs 14个月(HR 0.36,95% CI 0.22-0.59,P=0.002)。
- 联合组1年PFS和OS分别为67%和90%,对照组分别为35%和59%。
- 107例(72%)接受吉西他滨为基础化疗,31例(21%)接受mFFX。
关键数值与推荐
- SABR中位剂量33 Gy(范围20-45),143例为5分次,6例为3或6分次。
- SABR剂量≥40 Gy联合mFFX组(n=21)较吉西他滨化疗联合SABR<40 Gy组PFS和OS更优。
临床怎么用
- 对不可切除胰腺癌患者,可考虑mFFX联合5分次SABR剂量≥40 Gy的方案,但需注意该结论来自回顾性研究。
局限性
- 本研究为单中心回顾性分析,样本量有限,SABR≥40 Gy联合mFFX组仅21例,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to report the long-term impact of modern chemotherapy and SABR dose regimens on oncologic outcomes of unresectable pancreatic adenocarcinoma (PA). MATERIALS AND METHODS: We reviewed the treatment characteristics and outcomes of all patients who received multi-fraction SABR for unresectable PA between February 2007 and August 2018 at our institution. Time-to-events were calculated from date of diagnosis treating death as a competing risk. RESULTS: A total of 149 patients were identified. Median follow-up was 15 months (range: 5-47). Median SABR dose was 33 Gy (range: 20-45) delivered in 5 fractions in 143 patients, and 3 or 6 fractions in 6 patients. 107 patients (72%) received gemcitabine-based chemotherapy while 31 (21%) received modified FOLFIRINOX (mFFX). Median OS was 16 months (95% CI, 14-17), with a 1-year cumulative incidence of LF of 14%. The combination of SABR doses ≥40 Gy and mFFX (n = 21) showed a superior PFS and OS to the use of GEM-based chemotherapy with <40 Gy SABR doses (median PFS: 14 vs. 10 months, HR: 0.46, 95% CI: 0.29-0.71, P = 0.003; median OS: 24 vs. 14 months, HR: 0.36, 95% CI: 0.22-0.59, P = 0.002), with 1-year PFS and OS of 67% and 90% compared to 35% and 59% for those who received GEM-based chemotherapy with <40 Gy SABR doses, respectively. CONCLUSIONS: The use of mFFX and a SABR dose ≥40 Gy in 5 fractions may be superior compared to regimens that utilize gemcitabine-based chemotherapy or SABR doses <40 Gy.
引用
- Toesca DAS, Ahmed F, Kashyap M, et al. Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiother Oncol. 2020. PMID: 32763253. doi:10.1016/j.radonc.2020.07.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。